



**HAL**  
open science

## **Extrapyramidal side effects of antipsychotics: prevalence and risk factors. Results from the national FACE-SZ cohort** Cover title **Extrapyramidal side effects and antipsychotics**

David Misdrahi, Arnaud Tessier, Antoine Daubigney, Wassilios G. Meissner, Franck Schürhoff, Laurent Boyer, Ophelia Godin, Ewa Bulzacka, Bruno Aouizerate, Meja Andrianarisoa, et al.

### ► **To cite this version:**

David Misdrahi, Arnaud Tessier, Antoine Daubigney, Wassilios G. Meissner, Franck Schürhoff, et al.. Extrapyramidal side effects of antipsychotics: prevalence and risk factors. Results from the national FACE-SZ cohort Cover title Extrapyramidal side effects and antipsychotics. *The Journal of clinical psychiatry*, 2019, 80 (1), 10.4088/JCP.18m12246 . hal-02473295

**HAL Id: hal-02473295**

**<https://amu.hal.science/hal-02473295>**

Submitted on 10 Feb 2020

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

## **Title page**

### ***Title***

Extrapyramidal side effects of antipsychotics: prevalence and risk factors. Results from the national FACE-SZ cohort

### ***Cover title***

Extrapyramidal side effects and antipsychotics

### ***Authors***

MISDRAHI David <sup>a,b</sup>, MD; TESSIER Arnaud <sup>a,b</sup>, MSc; DAUBIGNEY Antoine <sup>c</sup>, MD; MEISSNER Wassilios G <sup>c</sup>, MD PhD; SCHURHOFF Franck <sup>a,m</sup>, MD PhD; BOYER Laurent <sup>o</sup>, MD PhD; GODIN Ophélie <sup>a,p</sup>, MSc; BULZACKA Ewa <sup>a,m</sup>, MSc; AOUIZERATE Bruno <sup>a,d</sup>, MD PhD; ANDRIANARISOA Meja <sup>a,m</sup>, MD; BERNA Fabrice <sup>a,e</sup>, MD PhD; CAPDEVIELLE Delphine <sup>a,f</sup>, MD PhD; CHEREAU-BOUDET Isabelle <sup>ag</sup>, MD; D'AMATO Thierry <sup>a,i</sup>, MD PhD; DUBERTRET Caroline <sup>a,h</sup>, MD PhD; DUBREUCQ Julien <sup>a,j</sup>, MD; FAGET-AGIUS Catherine <sup>a,k</sup>, MD; LANÇON Christophe <sup>a,k</sup>, MD PhD; MALLET Jasmina <sup>a,h</sup>, MD; PASSERIEUX Christine <sup>a,l</sup>, MD PhD; REY Romain <sup>a,i</sup>, MD; SCHANDRIN Aurélie <sup>a,n</sup>, MD; URBACH Mathieu <sup>a,l</sup>, MD; VIDAILHET Pierre <sup>a,e</sup>, MD PhD; LLORCA Pierre-Michel <sup>ag</sup>, MD PhD; FOND Guillaume <sup>a</sup>, MD PhD; for the FACE-SZ (FondaMental Academic Centers of Expertise for Schizophrenia) group\*

**<sup>a</sup> FondaMental Foundation**

**<sup>b</sup> Department of Adult Psychiatry, Charles Perrens Hospital, F-33076 ; Bordeaux University, CNRS UMR 5287-INCIA, Bordeaux, France.**

**<sup>c</sup> Neurology Department, Pellegrin Hospital, Bordeaux University Hospital, F-33076 Bordeaux, France. Institute of Neurodegenerative Diseases, Bordeaux University, UMR 5293, 33000 Bordeaux, France.**

**<sup>d</sup> Department of Adult Psychiatry, Charles Perrens Hospital, F-33076 Bordeaux, France; Laboratory of Nutrition and Integrated Neurobiology (UMR INRA 1286), Bordeaux University, France.**

<sup>e</sup> Strasbourg University Hospital, Strasbourg University, INSERM U1114, Federation of Translational Psychiatry, Strasbourg, France

<sup>f</sup> Academic Department of Adult Psychiatry, La Colombière Hospital, CHRU Montpellier, Montpellier University, Inserm 1061, Montpellier, France.

<sup>g</sup> CMP B, CHU, EA 7280 Medecine Department, Auvergne University, BP 69 63003 Clermont-Ferrand Cedex 1, France.

<sup>h</sup> AP-HP, Département of Psychiatry, Louis Mourier Hospital, Colombes, Inserm U894 Paris Diderot University, Sorbonne Paris Cité, Medecine Department, France.

<sup>i</sup> INSERM U1028, CNRS UMR5292, Neurosciences Research Center of Lyon, Claude Bernard University, PSYR2 team, Le Vinatier, Hospital, 69678 Bron Cedex, France.

<sup>j</sup> Psychosocial Rehabilitation Reference Centre, Alpes Isère Hospital, Grenoble, France.

<sup>k</sup> AP-HM, Academic Department of Psychiatry, Marseille, France.

<sup>l</sup> Department of Adult Psychiatry, Versailles Hospital, Le Chesnay, EA 4047 HANDIReSP, Versailles Saint-Quentin en Yvelines University, Versailles, France.

<sup>m</sup> INSERM U955, Translational Psychiatry Team, Créteil, France, Paris-Est Créteil University, DHU Pe-PSY, Psychiatry and Addictions Department, Henri Mondor Hospital, Créteil, France.

<sup>n</sup> Carémeau Hospital, Nîmes, France

<sup>o</sup> Aix-Marseille University, Medecine department - Timone, EA 3279: CEReSS - Study and Research center on Health Services and Quality of Life, 13005 Marseille, France

<sup>p</sup> Sorbonne University, UPMC University of Paris, UMR\_S 1136, Pierre Louis institute of Epidemiology and Public Health, F-75013, Paris, France

\*FACE-SCZ Group

Andrianarisoa M <sup>a,e</sup>, MD; Aouizerate B <sup>a,b</sup>, MD PhD; Bazin N <sup>a,l</sup>, MD; Berna F <sup>a,c</sup>, MD PhD; Blanc O <sup>a,d</sup>, Msc; Brunel L <sup>a,e</sup>, Msc; Bulzacka E <sup>a,e</sup>, Msc; Capdevielle D <sup>a,f</sup>, MD PhD; Chereau-Boudet I <sup>a,d</sup>, MD; Chesnoy-Servanin G <sup>a,g</sup>, Msc; Coulon N <sup>a,e</sup>, MD PhD; Danion Jm <sup>a,c</sup>, MD; D'Amato T <sup>a,g</sup>, MD PhD; Deloge A <sup>a,h</sup>, MD; Delorme C <sup>a,i</sup>, Msc; Denizot H <sup>a,d</sup>, MD; Dorey JM <sup>a,g</sup>, MD; Dubertret C <sup>a,j</sup>, MD PhD; Dubreucq J <sup>a,i</sup>, MD; Faget-Agius C <sup>a,k</sup>, MD; Fluttaz C <sup>a,i</sup>, Msc; Fond G <sup>a</sup>, MD PhD; Fonteneau S <sup>a,l</sup>, Msc; Gabayet F <sup>a,i</sup>, Msc; Giraud-Baro E <sup>a,i</sup>, MD; Jarroir M <sup>a,l</sup>, MsC;

Lacelle D <sup>a,d</sup> , Msc; Lançon C <sup>a,k</sup> , MD PhD; Laouamri H <sup>a</sup> , Msc; Leboyer M <sup>a,e</sup> , MD PhD; Le Gloahec T <sup>a,e</sup> , Msc; Le Strat Y <sup>a,j</sup> , MD PhD; Llorca PM <sup>a,d</sup> , MD PhD; Mallet J <sup>a,j</sup> , MD; Metairie E <sup>a,k</sup> , Msc; Misdrahi D <sup>a,h</sup> , MD; Offerlin-Meyer I <sup>a,c</sup> , PhD; Passerieux C <sup>a,l</sup> , MD PhD; Peri P <sup>a,k</sup> , Msc; Pires S <sup>a,d</sup> , Msc; Portalier C <sup>a,j</sup> , Msc; Ramet L <sup>a,l</sup> , Msc; Rey R <sup>a,g</sup> , MD; Roman C <sup>a,i</sup> , Msc; Schandrin A <sup>a,m</sup> , MD; Schürhoff F <sup>a,e</sup> , MD PhD; Tessier A <sup>a,h</sup> , Msc; Tronche AM <sup>a,d</sup> , MD; Urbach M <sup>a,l</sup> , MD; Vaillant F <sup>a,k</sup> , Msc; Vehier A <sup>a,g</sup> , Msc; Vidailhet P <sup>a,c</sup> , MD PhD; Vilà E <sup>a,h</sup> , Msc; Yazbek H <sup>a,f</sup> , Msc; Zinetti-Bertschy A <sup>a,c</sup> , Msc.

**<sup>a</sup> FondaMental Foundation**

**<sup>b</sup> Department of Adult Psychiatry, Charles Perrens Hospital, F-33076 Bordeaux, France; Laboratory of Nutrition and Integrated Neurobiology (UMR INRA 1286), Bordeaux University, France**

**<sup>c</sup> Strasbourg University Hospital, Strasbourg University, INSERM U1114, Federation of Translational Psychiatry, Strasbourg, France**

**<sup>d</sup> CMP B, CHU, EA 7280 Medecine Department, Auvergne University, BP 69 63003 Clermont-Ferrand Cedex 1, France**

**<sup>e</sup> INSERM U955, Translational Psychiatry Team, Créteil, France, Paris-Est Créteil University, DHU Pe-PSY, Psychiatry and Addictions Department, Henri Mondor Hospital, Créteil, France**

**<sup>f</sup> Academic Department of Adult Psychiatry, La Colombière Hospital, CHRU Montpellier, Montpellier University, Inserm 1061, Montpellier, France**

**<sup>g</sup> INSERM U1028, CNRS UMR5292, Neurosciences Research Center of Lyon, Claude Bernard University, PSYR2 team, Le Vinatier, Hospital, BP 30039, 69678 Bron Cedex, France**

**<sup>h</sup> Department of Adult Psychiatry, Charles Perrens Hospital, F-33076 ; Bordeaux University, CNRS UMR 5287-INCIA, Bordeaux, France**

**<sup>i</sup> Psychosocial Rehabilitation Reference Centre, Alpes Isère Hospital, Grenoble, France**

**<sup>j</sup> AP-HP, Departement of Psychiatry, Louis Mourier Hospital, Colombes, Inserm U894 Paris Diderot University, Sorbonne Paris Cité, Medecine Department, France**

**<sup>k</sup> AP-HM, Academic Department of Psychiatry, Marseille, France**

**<sup>l</sup> Department of Adult Psychiatry, Versailles Hospital, Le Chesnay, EA 4047 HANDIReSP, Versailles Saint-Quentin en Yvelines University, Versailles, France**

**<sup>m</sup> Carémeau Hospital, Nîmes, France**

***Corresponding author***

Docteur David Misdrahi : Centre Hospitalier Charles Perrens, F-33076 Bordeaux, France; Université de Bordeaux ; CNRS UMR 5287-INCIA. "Neuroimagerie et cognition humaine".  
Tel : +33 5 56 56 34 49 Fax : +33 5 56 56 17 14 ; e-mail: [david.misdrahi@u-bordeaux.fr](mailto:david.misdrahi@u-bordeaux.fr)

***Words count***

Total word count for the manuscript: 2651 words

Total word count for abstract: 246 words

***Keywords***

Schizophrenia; Antipsychotic; Side-effects; Extrapiramidal symptoms; Tardive dyskinesia

***Itemized list of tables and figures***

**Table 1.** Clinical characteristics of the Whole Sample.

**Table 2a.** Factors associated with Drug Induced Parkinsonism according to Simpson-Angus Scale (SAS) in a sample of 674 patients with schizophrenia.

**Table 2b.** Prevalence of Drug Induced Parkinsonism (DIP) according to the administered drugs in mono or polytherapy.

**Table 3a.** Factors associated with tardive dyskinesia (TD) according to Abnormal Involuntary Movement Scale (AIMS) in a sample of 674 patients with schizophrenia.

**Table 3b.** Prevalence of Tardive Dyskinesia (TD) according to the administered drugs in mono or polytherapy.

## **Abstract**

**Background:** Extrapyrarnidal side effects (EPS) have been identified as a complication of antipsychotic treatment. Previous meta-analyses have investigated EPS prevalence and risk factors in randomized clinical trials with highly selected patients, but studies in real-world schizophrenia are missing.

**Objectives:** To examine the prevalence and clinical correlates associated with EPS in a non-selected national multicentric sample of stabilized patients with schizophrenia.

**Method:** Between 2010 and 2016, patients suffering from schizophrenia (DSM-IV-TR) were recruited through the FondaMental Academic Centers of Expertise for Schizophrenia (FACE-SZ) network and data were collected during a comprehensive 1-day long standardized evaluation. The Simpson and Angus Scale and the Abnormal Involuntary Movement Scale were used to assess respectively Drug-Induced Parkinsonism (DIP) and Tardive Dyskinesia (TD).

**Results:** The overall prevalence of DIP and TD was respectively 13.2% and 8.3% in our community-dwelling sample of 674 patients. DIP was associated with negative symptoms (PANSS sub-score) (aOR = 1.102,  $p < .001$ ), First Generation Antipsychotic (FGA) (aOR = 2.038,  $p = .047$ ) and anticholinergic drug administration (aOR = 2.103,  $p = .017$ ) independently of sex, age, disorganization, and antipsychotic polytherapy. TD was associated with PANSS disorganized factor (aOR = 1.103,  $p = .049$ ) independently of sex, age, negative symptoms, excitation, first-generation antipsychotic, benzodiazepine and anticholinergic drug administration.

**Conclusion:** Our results indicate the high prevalence of EPS in a non-selected community-dwelling clinically stable sample of outpatients with schizophrenia. EPS should be systematically evaluated, especially in case of negative symptoms and disorganization or cognitive alteration in the monitoring of antipsychotic treatment. Monotherapy with an SGA should be preferentially initiated for patients with these sides-effects.

## **Introduction**

Extrapyramidal side effects including Drug Induced Parkinsonism (DIP) and Tardive Dyskinesia (TD) were identified as frequent side-effects of antipsychotics and have been associated with impaired quality of life <sup>1</sup> and depression <sup>2</sup> in patients with schizophrenia.

More specifically, parkinsonism (bradykinesia, rigidity, and tremor) occurs after a relatively short period of antipsychotic treatment <sup>3</sup> and has been mainly related to the intrinsic antidopaminergic potency of the antipsychotic treatment <sup>4-7</sup>. DIP symptoms usually recover within a few months after medication withdrawal <sup>8</sup>, while it may unmask neurodegenerative dopamine denervation in some patients <sup>9,10</sup>. Clinical studies have underlined that parkinsonism was positively correlated with the intensity of negative symptoms <sup>11,12</sup>.

TD is a drug-induced movement disorder, mainly related to antipsychotic treatment and defined by involuntary, repetitive orofacial movements, often accompanied by choreiform movements of the upper extremities. The term ‘tardive’ means delayed after months of antipsychotic treatment <sup>13,14</sup>. TD can be difficult to treat and may be permanent in some people. Age, duration of treatment with antipsychotics, first generation antipsychotic (FGA) treatment, treatment with anticholinergics, substance abuse and negative symptoms have been suggested to be associated with TD <sup>15</sup>.

EPS has been recently investigated in two comprehensive meta-analyses including clinical trials to compare second-generation antipsychotics (SGA) with FGA <sup>16,17</sup>. Overall, SGA including clozapine, olanzapine and risperidone have been found to be associated with fewer EPS than haloperidol (FGA). However, clinical trials are not representative of “real world” schizophrenia, as many patients are administered antipsychotic polytherapy combined with other psychotropic drugs (antidepressant, anxiolytic, anticholinergic) with various degrees of adherence and drug comorbidities, especially daily tobacco smoking that may impact antipsychotic blood levels <sup>11,18-20</sup>.

The objective of the present study was to determine the prevalence and clinical correlates associated with antipsychotic extrapyramidal side effects in a non-selected national sample of stabilized community-dwelling outpatients with schizophrenia.



## **Method**

### ***Study participants***

The FondaMental Academic Centers of Expertise for Schizophrenia (FACE-SZ) cohort is based on a French national network of 10 Schizophrenia Expert Centers (Bordeaux, Clermont-Ferrand, Colombes, Créteil, Grenoble, Lyon, Marseille, Montpellier, Strasbourg, and Versailles), set up by a scientific cooperation foundation in France, the FondaMental Foundation ([www.fondation-fondamental.org](http://www.fondation-fondamental.org)) and created by the French Ministry of Research in order to create a platform that links thorough and systematic assessment to research. Clinically stable patients aged above 16 years are referred by their general practitioner or psychiatrist, who subsequently receives a detailed evaluation report with suggestions for personalized interventions. The patients diagnosed with schizophrenia or schizoaffective disorders according to DSM-IV-TR criteria were enrolled in the FACE-SZ cohort. This study includes patients recruited between March 2010 and January 2016 <sup>21</sup>.

The assessment protocol was approved by the relevant ethical review board (CPP-Ile de France IX, January 18th, 2010). All subjects gave their informed consent prior to their inclusion in the study.

### ***Data collection***

#### ***Socio demographic and clinical variables***

Clinical and socio-demographic factors were collected during an extensive evaluation. Standardized assessments were used to assess psychotic and negative symptoms and general psychopathology with the Positive and Negative Syndrome Scale (PANSS) subscores <sup>22</sup>. For the purpose of this study and to explore specifically depressive and cognitive symptoms, we used the validated five-factor model of the PANSS <sup>23</sup> described as follows: “positive symptoms”; “negative symptoms”; disorganized/concrete factor accounted for the largest share with cognition (IQ); “excitement” and “depression”. Depressive symptoms were also assessed with the French-validated Calgary Depression Rating Scale for Schizophrenia (CDRS) <sup>24</sup>. A cut-off of 6 was considered as a current major depressive episode. Treatment adherence was evaluated using the Brief Adherence Rating Scale (BARS) <sup>25</sup> and the Medication Adherence Rating Scale <sup>26</sup>. Daily tobacco smoking,

alcohol and cannabis use disorder was defined according to SCID 1.0. Ongoing type and number of psychotropic treatment was recorded (antipsychotics, antidepressant, benzodiazepines and anticholinergic). Chlorpromazine equivalent doses (CPZ100eq) were calculated according to the minimum effective dose method<sup>27</sup>. All patients were on stable medication for more than 4 weeks.

#### *Drug Induced Parkinsonism (DIP)*

The Simpson and Angus Scale (SAS) is a 10-item scale used in the evaluation of clinical and research practices to assess DIP. One item measures gait, six items measure stiffness and three items measure tremor, salivation and palpebral reflex respectively. This scale is validated and among those most used in individuals with schizophrenia in naturalistic conditions<sup>28</sup>. We used a cut-off at 0.65 to define presence of DIP. This threshold was previously used and validated<sup>29</sup>.

#### *Tardive Dyskinesia (TD)*

The Abnormal Involuntary Movement Scale (AIMS) is a 10-item scale designed to record the occurrence of dyskinetic movements, which was used to assess the incidence of TD<sup>30</sup>. Items evaluate dyskinetic movements in three body regions (facial and oral, extremity, trunk) on a 5-point scale (with 0 indicating no dyskinetic movements and 4 indicating severe dyskinetic movements) for a total score ranging from 0 to 40. Dyskinesia was classified as present in a particular subject with an AIMS score of at least three (moderate degree) in any body part or with at least two (mild degree) in two or more body parts (Schooler-Kane criteria)<sup>20</sup>. Each item on the AIMS ranges from 0 to 4, and the total AIMS score was calculated by adding items 1–7.

#### *Statistical Analysis*

The socio-demographic and clinical characteristics, presence of substance use disorder, medications, and the scores for each scale were compared between the two groups for each side-effect studied (“DIP” vs “No DIP” and “TD” vs “No TD”) using the Student’s t-test for continuous variables and Chi-squared test for categorical variables. A logistic regression analysis was used to estimate the odd ratios (OR) for risk factors associated with DIP and TD, after adjusting for confounding factors. Variables relevant to the model were selected based on their clinical interest and/or a threshold p-value  $\leq 0.20$  in univariate analyses (exclusion of collinear variables). The final model incorporated the

adjusted odd ratios (aOR) with 95% confidence interval. An aOR > 1 was considered as an increased risk factor for the presence of studied side effect, and an aOR < 1 as a protective risk factor for studied side-effects. The statistical significance level was set at  $p = 0.05$  in a two-sided test. Data were analyzed using SPSS 20.0 software.

## Results

### *Sample characteristics*

Altogether, 674 outpatients suffering from schizophrenia were included in this study. Clinical and demographic characteristics are presented in Table 1. Patients were mostly men (73.3%), the average age at inclusion was 32.6 years (SD = 9.9) and the mean illness duration was 11.0 years (SD = 8.2). 52.8% were current tobacco smokers, and current alcohol and cannabis use disorders accounted respectively for 9.1% and 13.7%. SGAs were prescribed in 90.8% of patients, 114 (20.2%) patients were administered an anticholinergic drug, and 214 patients (37.9%) were treated with antipsychotic combination therapy.

### *Drug Induced Parkinsonism*

The global prevalence of DIP in our sample was 13.2% (89/674). In the multivariate analysis, after adjustment for sex, age, disorganization, and antipsychotic polytherapy, DIP remained significantly associated with higher negative symptoms (PANSS subscore, aOR = 1.102, [1.055–1.151],  $p < .001$ ), prescription of FGA (aOR = 2.038, [1.010–4.111],  $p = .047$ ) and coprescription of an anticholinergic drug (aOR = 2.103, [1.143–3.869],  $p = .017$ ) (Table 2a). Concerning PANSS negative factor, all items (which include N1 (Blunted affect), N2 (Emotional withdrawal), N3 (Poor rapport), N4 (Passive/apathetic social withdrawal), N6 (Lack of spontaneity and flow of conversation) and G7 (Motor retardation) items) scored significantly higher in patients with DIP.

The detail of the administered antipsychotics and the related proportion of patients with DIP are presented in Table 2b. By analyzing all drugs, only quetiapine was associated with a lower rate of DIP (2.2% vs. 8.6%,  $p = .047$ ).

### *Tardive Dyskinesia*

The overall prevalence of tardive dyskinesia was 8.3% (56/674). Thirteen patients (1.9%) had both these two extrapyramidal side effects (DIP and TD).

In the multivariate analysis, after adjustment for confounding factors (sex, age, negative symptoms, excitation, FGA, benzodiazepine and anticholinergic drug administration), TD remained

significantly associated with higher disorganization level (PANSS sub score, aOR = 1.103, [1.000–1.217],  $p = .049$ ) (Table 3a). The PANSS disorganized factor is composed of P2 (Conceptual disorganization), N5 (Difficulty in abstract thinking) and G11 (Poor attention) items, which were significantly higher in patients with TD.

The TD frequency according to antipsychotic classes is presented in Table 3b. By analyzing all drugs, patients with TD had a higher prescription rate of chlorpromazine (3.6% vs. 0.3%,  $p=.032$ ) and haloperidol (16.1% vs. 7%,  $p=.013$ ) than those without TD.

## Discussion

Our major findings may be summarized as follows: the overall prevalence of DIP and TD was respectively 13.2% and 8.3% in a national stabilized community-dwelling sample of 674 outpatients with schizophrenia. After adjustment for confounding factors, DIP remained significantly associated with higher negative symptoms level, FGA and anticholinergic administration while TD remained only significantly associated with higher disorganization symptoms level.

The DIP rate was 13.2 % in the present study. This is the lower rate of all published studies to date (with DIP ranging from 14% to 40%<sup>6,31-34</sup>). The different scales and thresholds, different treatments and populations' characteristics may explain this discrepancy. In the current study the threshold of 0.65 was used to increase the scale's specificity (62%)<sup>29</sup>. This choice may contribute to an underestimation of DIP prevalence in this sample of community-dwelling stabilized outpatients.

The present results confirm that the risk for DIP was associated with current FGA administration in real-world schizophrenia. This is consistent with the results of a large meta-analysis including only randomized controlled trials with highly-selected patients (i.e. with good compliance and without comorbidities and suicide risk)<sup>16</sup>. Descriptive analyses show that patients with DIP are mostly (56.4%) treated with antipsychotic combination therapy (18.2% with a FGA/FGA combination, 27.3% with a SGA/SGA combination and 54.5% with a FGA/SGA combination), and 43.6% with a single antipsychotic (14.7% with a FGA monotherapy and 85.3% with a SGA monotherapy). While these results are only cross-sectional, it may be reasonably suggested that antipsychotic combination should be avoided as soon as possible in patients with DIP, especially when associated with negative symptoms. Polytherapy has never been associated with higher effectiveness to date<sup>35</sup>, which suggests that the benefit/risk ratio is in favor of monotherapy, especially in cases of DIP and negative symptoms. Future interventional studies should determine if switching from polytherapy to antipsychotic monotherapy might alleviate both DIP and negative symptoms.

Patients with anticholinergic treatment had significantly more DIP. This result is plausibly due to the prescription bias: patients with higher DIP are more prone to be prescribed anticholinergic by their psychiatrists. However, these results suggest that anticholinergics are not sufficient to correct DIP

in real-world SZ subjects, due to a potential under-dosage or insufficient effectiveness. This result is consistent with the results from a recent meta-analysis<sup>16</sup>, which found that clozapine and olanzapine induced significantly fewer DIP than the FGA-anticholinergic association. Moreover, anticholinergic drugs have been associated with cognitive impairment in SZ subjects<sup>36</sup>. Altogether, these results suggest that in case of persistent DIP under FGA and anticholinergic drug prescription, the treatment should be switched to SGA if possible.

DIP has been associated with higher negative symptoms in the present sample, which is consistent with the results of previous studies<sup>11,37</sup>. This co-occurrence has been suggested to be due to a common neurobiological basis<sup>38,39</sup>. The strong associations between negative and motor features in antipsychotic-treated subjects may be explained by drug-induced negative symptoms and motor signs as a consequence of drug-related dopamine blockade<sup>40</sup> with a possible direct neurotoxic effect of antipsychotics on dopamine neurons<sup>41</sup>. Motor symptoms may be related to the dysfunction of the nigrostriatal dopaminergic system while negative symptoms may be the consequence of blocking receptors of the meso-cortico-limbic dopaminergic system. Beyond motor symptoms, patients with Parkinson's disease also show bradyphrenia (G7), as well as many of the negative symptoms (N1 (Blunted affect), N2 (Emotional withdrawal), N4 (Passive/apathetic social withdrawal), N5 (Difficulty in abstract thinking), N6 (Lack of spontaneity and flow of conversation)), at least in part, because of impaired function of meso-cortico limbic neurons. Similarly to Parkinson's disease, dopaminergic neurons degeneration has been identified in 45% SZ subjects with a two years SPECT follow-up, which suggested the potential benefit of levodopa therapy in this subgroup<sup>9</sup>.

In a recent meta-analysis including 41 studies (11,493 patients, mean age = 42.8 years) using the same scale and cut-off (AIMS with Schooler-Kane criteria)<sup>20</sup>, the global mean TD prevalence was 25.3% (95% CI = 22.7%–28.1%) vs. 7.2% in the four studies including only FGA-naive patients. In the present sample, 27.2% of the sample was currently prescribed at least one FGA, however the TD prevalence was only 8.3%. The prevalence of TD was therefore lower than expected in the present sample, which may be due to sociodemographic characteristics, especially the relatively young age of the present sample (32.6 years). This may also explain the absence of significant association between

TD and age in the present sample, which is inconsistent with previous results<sup>15,20,42</sup>. The present study did not report the lifetime prescription of antipsychotic, which is a limit. Future studies should include the total number of antipsychotic treatment and the mean dose / mean duration of exposure for each antipsychotic treatment. Altogether, these studies combined with the present study underlie the difficulty to define and assess TD<sup>43</sup>. These inconsistent results are due to the differences of the following factors including population age (higher age), sex, region (high geographical variation), medication type and dosing (higher rates during FGA than during SGA treatment), duration of treatment, the duration of illness<sup>20</sup>.

TD has been associated with higher disorganized/cognitive score in the current study<sup>23</sup>. This factor was highly correlated with cognitive functions evaluated with the WAIS IQ and general cognitive ability<sup>23</sup>. This is consistent with previous studies suggesting that TD was associated with cognitive impairment such as orientation, memory, silence, attention and muteness in schizophrenia<sup>44-47</sup>. It has been suggested that this association was mediated by decreased Brain-Derived Neurotrophic Factor (BDNF), which may play a critical role in cognitive function and may reflect a compensatory response to severe cerebral damages<sup>48,49</sup>. Future studies should explore the specific cognitive functions associated with TD in real world schizophrenia, and determine which intervention may be effective in improving both TD and cognitive functioning in SZ subjects with TD. It has been hypothesized that TD may result primarily from antipsychotics' induced dopamine supersensitivity in the nigrostriatal pathway (D2 dopamine receptor)<sup>50</sup>. This would be consistent with observations of Parkinson's disease in which dyskinesia is induced by an "overdose" of dopaminergic treatment, which may also result in positive psychotic symptoms<sup>51</sup>. Cognitive evaluations should be carefully evaluated when evaluating the benefit/risk ratio of switching or adjusting antipsychotic treatment in case of iatrogenic TD.

Our study has several limitations. The cross-sectional design does not allow us to infer the causal nature of the observed associations. Secondary negative symptoms have not been differentiated from primary negative symptoms in the present study. Differentiating primary from secondary negative symptoms remains difficult in populations with long duration of illness due to the memory



bias and is adapted for prospective studies. As above-mentioned, lifetime exposure to antipsychotics was not reported due to memory bias, as some patients had more than 10 years of illness duration.

### ***Conclusion***

The present findings suggest a high prevalence of DIP and TD in a relatively young sample of SZ subjects with a mean illness duration of almost 11 years, as well as a complex relationship with respectively negative (for DIP) and disorganized/cognitive (for TD) symptomatology. More than one quarter of the subjects were administered FGA, and were found to have higher DIP levels despite of the prescription of anticholinergic drugs. SGA monotherapy appears to be the best strategy to date to improve DIP in SZ subjects. The benefit-risk ratio of switching the treatment for SGA monotherapy should be carefully evaluated in case of DIP and/or TD in patients with FGA and/or anticholinergic drug prescription.

### ***Clinical Points:***

## **Statements**

### ***Acknowledgments and funding source***

This work was funded by the hospital Charles-Perrens, by the AP-HP (Assistance Publique des Hôpitaux de Paris), AP-HM (Assistance Publique des Hôpitaux de Marseille), Fondation FondaMental (RTRS Santé Mentale), by the Investissements d’Avenir program managed by the ANR under reference ANR-11-IDEX-0004-02 and ANR-10-COHO-10-01, and by INSERM (Institut National de la Santé et de la Recherche Médicale). We express all our thanks to the nurses, and to the patients who were included in the present study. We thank Hakim Laouamri M.Sc (FondaMental Foundation), and his team (Stéphane Beaufort, M.Sc; Seif Ben Salem, M.Sc; Karmène Souyris, M.Sc; Victor Barteau, M.Sc; and Mohamed Laaidi, M.Sc) for the development of the FACE-SZ computer interface, data management, quality control and regulatory aspects. Thanks for critical reading and the neurological point of view to Prof. François Tison (MD, PhD) and Prof. Dominique Guehl (MD, PhD) of Bordeaux University Hospital. All these peoples reports no conflicts of interest with this study.

### ***Role of the funding agency***

Fondation Fondamental (RTRS Santé Mentale) provided data management support. Hospital Charles-Perrens, AP-HP (Assistance Publique des Hôpitaux de Paris), AP-HM (Assistance Publique des Hôpitaux de Marseille) and Investissements d’Avenir program had no role in the conduct or publication of the study.

### ***Conflicts of interest***

None

### ***Contributors***

AT and AD performed the statistical analysis. AT, AD and DM wrote the first complete manuscript. PML, GF and WGM edited earlier versions of the manuscript for important intellectual content. All authors were involved in the patients’ recruitment, the clinical evaluation, acquisition of the clinical data and approved the final manuscript.

### ***Patient consent***

All subjects gave their informed consent prior to their inclusion in the study.

***Ethics approval***

The assessment protocol was approved by the relevant ethical review board (CPP-Ile de France IX, January 18th, 2010). This study has, therefore, been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.

## References

1. Browne S, Roe M, Lane A, et al. Quality of life in schizophrenia: relationship to sociodemographic factors, symptomatology and tardive dyskinesia. *Acta Psychiatr Scand.* 1996;94(2):118-124.
2. Chang WC, Cheung R, Hui CLM, et al. Rate and risk factors of depressive symptoms in Chinese patients presenting with first-episode non-affective psychosis in Hong Kong. *Schizophr Res.* 2015;168(1-2):99-105. doi:10.1016/j.schres.2015.07.040
3. Munhoz RP, Bertucci Filho D, Teive HAG. Not all drug-induced parkinsonism are the same: the effect of drug class on motor phenotype. *Neurol Sci Off J Ital Neurol Soc Ital Soc Clin Neurophysiol.* November 2016. doi:10.1007/s10072-016-2771-y
4. Hasan A, Falkai P, Wobrock T, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. *World J Biol Psychiatry Off J World Fed Soc Biol Psychiatry.* 2013;14(1):2-44. doi:10.3109/15622975.2012.739708
5. Kane JM. Pharmacologic treatment of schizophrenia. *Biol Psychiatry.* 1999;46(10):1396-1408.
6. Novick D, Haro JM, Bertsch J, Haddad PM. Incidence of extrapyramidal symptoms and tardive dyskinesia in schizophrenia: thirty-six-month results from the European schizophrenia outpatient health outcomes study. *J Clin Psychopharmacol.* 2010;30(5):531-540. doi:10.1097/JCP.0b013e3181f14098
7. Pappa S, Dazzan P. Spontaneous movement disorders in antipsychotic-naive patients with first-episode psychoses: a systematic review. *Psychol Med.* 2009;39(7):1065-1076. doi:10.1017/S0033291708004716
8. Bower JH, Maraganore DM, McDonnell SK, Rocca WA. Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976-1990. *Neurology.* 1999;52(6):1214-1220.
9. Tinazzi M, Morgante F, Matinella A, et al. Imaging of the dopamine transporter predicts pattern of disease progression and response to levodopa in patients with schizophrenia and parkinsonism: a 2-year follow-up multicenter study. *Schizophr Res.* 2014;152(2-3):344-349. doi:10.1016/j.schres.2013.11.028
10. Tinazzi M, Cipriani A, Matinella A, et al. [123I]FP-CIT single photon emission computed tomography findings in drug-induced Parkinsonism. *Schizophr Res.* 2012;139(1):40-45. doi:10.1016/j.schres.2012.06.003
11. Rybakowski JK, Vansteelandt K, Remlinger-Molenda A, et al. Extrapyramidal symptoms during treatment of first schizophrenia episode: results from EUFEST. *Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol.* 2014;24(9):1500-1505. doi:10.1016/j.euroneuro.2014.07.001
12. Othman Z, Ghazali M, Razak A., Husain M. Severity of Tardive Dyskinesia and Negative Symptoms are Associated with Poor Quality of Life in Schizophrenia Patients (PDF Download Available). *Int Med J.* 2013;20:677-680.
13. Lerner PP, Miodownik C, Lerner V. Tardive dyskinesia (syndrome): Current concept and modern approaches to its management. *Psychiatry Clin Neurosci.* 2015;69(6):321-334. doi:10.1111/pcn.12270

14. Owens DG, Johnstone EC, Frith CD. Spontaneous involuntary disorders of movement: their prevalence, severity, and distribution in chronic schizophrenics with and without treatment with neuroleptics. *Arch Gen Psychiatry*. 1982;39(4):452-461.
15. Miller DD, McEvoy JP, Davis SM, et al. Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial. *Schizophr Res*. 2005;80(1):33-43. doi:10.1016/j.schres.2005.07.034
16. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. *Lancet Lond Engl*. 2009;373(9657):31-41. doi:10.1016/S0140-6736(08)61764-X
17. Rummel-Kluge C, Komossa K, Schwarz S, et al. Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons. *Schizophr Bull*. 2012;38(1):167-177. doi:10.1093/schbul/sbq042
18. Yoshida K, Bies RR, Suzuki T, et al. Tardive dyskinesia in relation to estimated dopamine D2 receptor occupancy in patients with schizophrenia: analysis of the CATIE data. *Schizophr Res*. 2014;153(1-3):184-188. doi:10.1016/j.schres.2014.01.017
19. Berna F, Misdrahi D, Boyer L, et al. Akathisia: prevalence and risk factors in a community-dwelling sample of patients with schizophrenia. Results from the FACE-SZ dataset. *Schizophr Res*. 2015;169(1-3):255-261. doi:10.1016/j.schres.2015.10.040
20. Carbon M, Hsieh C-H, Kane JM, Correll CU. Tardive Dyskinesia Prevalence in the Period of Second-Generation Antipsychotic Use: A Meta-Analysis. *J Clin Psychiatry*. January 2017. doi:10.4088/JCP.16r10832
21. Schürhoff F, Fond G, Berna F, et al. A National network of schizophrenia expert centres: An innovative tool to bridge the research-practice gap. *Eur Psychiatry J Assoc Eur Psychiatr*. 2015;30(6):728-735. doi:10.1016/j.eurpsy.2015.05.004
22. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. *Schizophr Bull*. 1987;13(2):261-276.
23. Wallwork RS, Fortgang R, Hashimoto R, Weinberger DR, Dickinson D. Searching for a consensus five-factor model of the Positive and Negative Syndrome Scale for schizophrenia. *Schizophr Res*. 2012;137(1):246-250. doi:10.1016/j.schres.2012.01.031
24. Lançon C, Auquier P, Reine G, Bernard D, Toumi M. Study of the concurrent validity of the Calgary Depression Scale for Schizophrenics (CDSS). *J Affect Disord*. 2000;58(2):107-115.
25. Byerly MJ, Nakonezny PA, Rush AJ. The Brief Adherence Rating Scale (BARS) validated against electronic monitoring in assessing the antipsychotic medication adherence of outpatients with schizophrenia and schizoaffective disorder. *Schizophr Res*. 2008;100(1-3):60-69. doi:10.1016/j.schres.2007.12.470
26. Misdrahi D, Tessier A, Swendsen J, et al. Determination of Adherence Profiles in Schizophrenia Using Self-Reported Adherence: Results From the FACE-SZ Dataset. *J Clin Psychiatry*. 2016;77(9):e1130-e1136. doi:10.4088/JCP.15m10115
27. Leucht S, Samara M, Heres S, Patel MX, Woods SW, Davis JM. Dose Equivalents for Second-Generation Antipsychotics: The Minimum Effective Dose Method. *Schizophr Bull*. 2014;40(2):314-326. doi:10.1093/schbul/sbu001

28. Knol W, Keijsers CJPW, Jansen PAF, van Marum RJ. Systematic evaluation of rating scales for drug-induced parkinsonism and recommendations for future research. *J Clin Psychopharmacol*. 2010;30(1):57-63. doi:10.1097/JCP.0b013e3181c914b3
29. Janno S, Holi MM, Tuisku K, Wahlbeck K. Validity of Simpson-Angus Scale (SAS) in a naturalistic schizophrenia population. *BMC Neurol*. 2005;5(1):5. doi:10.1186/1471-2377-5-5
30. Bark N, Florida D, Gera N, Varardi R, Harghel L, Adlington K. Evaluation of the routine clinical use of the Brief Psychiatric Rating Scale (BPRS) and the Abnormal Involuntary Movement Scale (AIMS). - Semantic Scholar. *J Psychiatr Pract*. 2011;17:300-303. doi:10.1097/01.pra.0000400269.68160.e6
31. Czobor P, Van Dorn RA, Citrome L, Kahn RS, Fleischhacker WW, Volavka J. Treatment adherence in schizophrenia: a patient-level meta-analysis of combined CATIE and EUFEST studies. *Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol*. 2015;25(8):1158-1166. doi:10.1016/j.euroneuro.2015.04.003
32. Hansen TE, Casey DE, Hoffman WF. Neuroleptic intolerance. *Schizophr Bull*. 1997;23(4):567-582.
33. Janno S, Holi M, Tuisku K, Wahlbeck K. Prevalence of neuroleptic-induced movement disorders in chronic schizophrenia inpatients. *Am J Psychiatry*. 2004;161(1):160-163. doi:10.1176/appi.ajp.161.1.160
34. Parksepp M, Ljubajev Ü, Täht K, Janno S. Prevalence of neuroleptic-induced movement disorders: an 8-year follow-up study in chronic schizophrenia inpatients. *Nord J Psychiatry*. 2016;70(7):498-502. doi:10.3109/08039488.2016.1164245
35. Correll CU, Rummel-Kluge C, Corves C, Kane JM, Leucht S. Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. *Schizophr Bull*. 2009;35(2):443-457. doi:10.1093/schbul/sbn018
36. Minzenberg MJ, Poole JH, Benton C, Vinogradov S. Association of anticholinergic load with impairment of complex attention and memory in schizophrenia. *Am J Psychiatry*. 2004;161(1):116-124. doi:10.1176/appi.ajp.161.1.116
37. Mentzel TQ, Lieverse R, Bloemen O, Viechtbauer W, van Harten PN, Genetic Risk and Outcome of Psychosis (GROUP) Investigators. High Incidence and Prevalence of Drug-Related Movement Disorders in Young Patients With Psychotic Disorders. *J Clin Psychopharmacol*. 2017;37(2):231-238. doi:10.1097/JCP.0000000000000666
38. Peralta V, Cuesta MJ. Negative parkinsonian, depressive and catatonic symptoms in schizophrenia: a conflict of paradigms revisited. *Schizophr Res*. 1999;40(3):245-253.
39. Docx L, Morrens M, Bervoets C, et al. Parsing the components of the psychomotor syndrome in schizophrenia. *Acta Psychiatr Scand*. 2012;126(4):256-265. doi:10.1111/j.1600-0447.2012.01846.x
40. Heinz A, Knable MB, Coppola R, et al. Psychomotor slowing, negative symptoms and dopamine receptor availability--an IBZM SPECT study in neuroleptic-treated and drug-free schizophrenic patients. *Schizophr Res*. 1998;31(1):19-26.
41. Rollema H, Skolnik M, D'Engelbronner J, Igarashi K, Usuki E, Castagnoli N. MPP(+)-like neurotoxicity of a pyridinium metabolite derived from haloperidol: in vivo microdialysis and in vitro mitochondrial studies. *J Pharmacol Exp Ther*. 1994;268(1):380-387.

42. Jeste DV, Lacro JP, Palmer B, Rockwell E, Harris MJ, Caligiuri MP. Incidence of tardive dyskinesia in early stages of low-dose treatment with typical neuroleptics in older patients. *Am J Psychiatry*. 1999;156(2):309-311. doi:10.1176/ajp.156.2.309
43. Tarsy D, Baldessarini RJ. Epidemiology of tardive dyskinesia: Is risk declining with modern antipsychotics? *Mov Disord*. 2006;21(5):589-598. doi:10.1002/mds.20823
44. Wegner JT, Catalano F, Gibraltar J, Kane JM. Schizophrenics with tardive dyskinesia. Neuropsychological deficit and family psychopathology. *Arch Gen Psychiatry*. 1985;42(9):860-865.
45. Waddington JL, Youssef HA. An unusual cluster of tardive dyskinesia in schizophrenia: association with cognitive dysfunction and negative symptoms. *Am J Psychiatry*. 1986;143(9):1162-1165. doi:10.1176/ajp.143.9.1162
46. Waddington JL, Youssef HA, Dolphin C, Kinsella A. Cognitive dysfunction, negative symptoms, and tardive dyskinesia in schizophrenia. Their association in relation to topography of involuntary movements and criterion of their abnormality. *Arch Gen Psychiatry*. 1987;44(10):907-912.
47. Byne W, White L, Parella M, Adams R, Harvey PD, Davis KL. Tardive dyskinesia in a chronically institutionalized population of elderly schizophrenic patients: prevalence and association with cognitive impairment. *Int J Geriatr Psychiatry*. 1998;13(7):473-479.
48. Wu JQ, Chen DC, Tan YL, et al. Cognition impairment in schizophrenia patients with tardive dyskinesia: association with plasma superoxide dismutase activity. *Schizophr Res*. 2014;152(1):210-216. doi:10.1016/j.schres.2013.11.010
49. Wu JQ, Chen DC, Tan YL, et al. Altered BDNF is correlated to cognition impairment in schizophrenia patients with tardive dyskinesia. *Psychopharmacology (Berl)*. 2015;232(1):223-232. doi:10.1007/s00213-014-3660-9
50. Seeman P. Schizophrenia and dopamine receptors. *Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol*. 2013;23(9):999-1009. doi:10.1016/j.euroneuro.2013.06.005
51. Hinkle JT, Perepezko K, Rosenthal LS, et al. Markers of impaired motor and cognitive volition in Parkinson's disease: Correlates of dopamine dysregulation syndrome, impulse control disorder, and dyskinesias. *Parkinsonism Relat Disord*. November 2017. doi:10.1016/j.parkreldis.2017.11.338